Dacarbazine in solitary fibrous tumor: A case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5192-5201

  Stacchiotti, S ^a,e   Tortoreto, M ^b   Bozzi, F ^c   Tamborini, E ^c   Morosi, C ^d   Messina, A ^d   Libertini, M ^a   Palassini, E ^a   Cominetti, D ^b   Negri, T ^c   Gronchi, A ^e   Pilotti, S ^c   Zaffaroni, N ^b   Casali, P G ^a  

^a Adult Sarcoma Medical Oncology Unit   (Italy)

^b Molecular Pharmacology Unit   (Italy)

^c Experimental Molecular Pathology Unit   (Italy)

^d Department of Radiology ^*  (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DACARBAZINE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPOGLYCEMIA; MALE; MGMT GENE; MOUSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PARANEOPLASTIC HYPOGLYCEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCID MOUSE; SOLITARY FIBROUS TUMOR; THROMBOCYTOPENIA; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SOLITARY FIBROUS TUMORS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884574360     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0776     Document Type: Article

References (30)

1. Fletcher C D M, et al., editors. World Health Organization (WHO) classification of tumours of soft tissue and bone. Pathology and Genetics. Lyon: IARC Press; 2013.
2. Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 2013;45:180-5.
3. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery 2008;63:720-6.
4. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer 1998;82:1915-20.
5. Ferigo N, Cottalorda J, Allard D, Gentil-Perret A, Fessy M, Berger C, et al. Successful treatment via chemotherapy and surgical resection of a femoral hemangiopericytoma with pulmonary metastasis. J Pediatr Hematol Oncol 2006;28:237-40.
6. Beadle GF, Hillcoat B L J. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. Surg Oncol 1983;22:167-70.
7. Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, et al. Response to chemotherapy of solitary fibrous tumor: a retrospective study. Eur J Cancer 2013;49:2376-83.
8. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117:4939-47.
9. Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res 2008;151:129-33.
10. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60.
11. Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma/solitary fibrous tumour. InvestNewDrugs 2010;28:199-202.
12. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, et al. Sunitinib in solitary fibrous tumor. Ann Oncol 2012;23:3171-9.
13. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancersoft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32.
14. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010;9:1286-97.
15. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-6.
17. Thomas RP, Recht L, Nagpal S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol 2013;5:1-9.
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: a novel PCR assay for methlation status of CpG islands. Prc Natl Acad Sci U S A 1996;93:9821-6.
19. Kaplan WE, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Najar HM, Dutz JP. Topical CpG enhances the response of murine malignant melanoma to dacarbazine. J Invest Dermatol 2008;128:2204-10.
21. Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS ONE 2012;7:e45492.
22. Cassinelli G, Zuco V, Petrangolini G, De Cesare M, Tortoreto M, Lanzi C, et al. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol 2012;84:163-71.
23. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012;18:4070-9.
24. Stevens MF, Newlands ES. From triazines and triazenes to temozolomide. Eur J Cancer 1993;29:1045-7.
25. Mosquera JM, Fletcher C D M. Expanding the spectrum of malignant progression solitary fibrous tumor - a study of 8 cases with a discrete anaplastic component - is this dedifferentiated SFT? Am J Surg Pathol 2009;33:1314-21.
26. Magro G, Emmanuele C, Lopes M, Vallone G, Greco P. Solitary fibrous tumour of the kidney with sarcomatous overgrowth. Case report and review of the literature. APMIS 2008;116:1020-5.
27. Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Pastorino U, et al. High-grade sarcomatous overgrowth in solitary fibrous tumor: a clinico-pathological study of 10 cases. Am J Surg Path 2012;36:1202-15.
28. Samulitis BK, Dorr RT, Chow HH. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. Anticancer Res 2011;31:2781-5.
29. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-36.
30. Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, et al. Methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010;103:820-6.